Search | Clinical Trials Finder

Conditions: Stage 1 Hypertension, Stage 2 Hypertension
Interventions: Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 4,161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 413
States / cities: Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more

Conditions: Hypertension
Interventions: Valsartan, Enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: Hydrochlorothiazide, Lisinopril, Lisinopril and Hydrochlorothiazide, Nifedipine XL, Metoprolol tartrate, Atenolol, Valsartan, Doxazosin, Clonidine, Hydralazine, Metoprolol succinate, Amlodipine; Drug
Lead sponsor: Creighton University; Other
Eligibility: 25 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hypertension
Interventions: Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more

Conditions: Hypertension
Interventions: Nebivolol, Valsartan, Nebivolol/valsartan combination; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypertension
Interventions: Nebivolol, Valsartan and Hydrochlorothiazide; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 135
States / cities: Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more

Conditions: Hypertension
Interventions: valsartan and amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy, Focal Segmental Glomerulosclerosis, Glomerulopathy (Obesity-associated), Glomerulonephritis, Membranous
Interventions: Aliskiren, Valsartan; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertrophic Cardiomyopathy
Interventions: Valsartan, Placebo; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 8 Years to 45 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 13
States / cities: Stanford, California • Aurora, Colorado • Chicago, Illinois + 8 more

Conditions: Hypertension, Stage 2 Hypertension, Diabetes
Interventions: Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 95
States / cities: Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more

Conditions: Stage 2 Hypertension
Interventions: Valsartan/aliskiren, Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Renal Insufficiency, Chronic, Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 42
States / cities: Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more

Conditions: Hypertension, Metabolic Syndrome
Interventions: Aliskerin/Valsartan and Rampiril; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Heart Failure
Interventions: LCZ696, valsartan, LCZ696 placebo, valsartan placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 38
States / cities: Beverly Hills, California • Sacramento, California • San Diego, California + 28 more

Conditions: Hypertension
Interventions: telmisartan, valsartan; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 16
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 12 more

Conditions: Post Acute Coronary Syndrome, Myocardial Ischemia
Interventions: Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Investigative Site, New Jersey

Conditions: Hypertension, Diabetes
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Salisbury, North Carolina

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healthy
Interventions: Aliskiren, Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: Azilsartan medoxomil, Valsartan, Olmesartan, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 86
States / cities: Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 30 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more

Conditions: Hypertension
Interventions: telmisartan 80 mg / hydrochlorothiazide 25 mg, valsartan 160 mg / hydrochlorothiazide 25 mg, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 113
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 90 more

Conditions: Chronic Heart Failure (CHF)
Interventions: LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years and older
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 52
States / cities: Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more

Conditions: Hypertension
Interventions: valsartan+amlodipine combination, valsartan, amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure

Black Education and Treatment of Hypertension (BEAT HTN)

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

24 Hour Ambulatory Cardiac Oxygen Consumption

Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients

Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients